Furthermore, our results are consistent with previous articles demonstrating that down-regulation of IMP1 activity suppresses cell growth in neuroblastoma, melanoma, and ovarian cancer cells and has a synergistic effect on controlling neuroblastoma cell proliferation in combination with cyclin-dependent kinase (CDK) inhibitors [21,33]. This evidence concerns the gene IGF2BP1 and ovarian carcinoma.